About Academician Jia Weiping
Academician Jia Weiping (贾伟平) is Chief Physician, Professor, Academician of the Chinese Academy of Engineering, and Director of the Department of Endocrinology and Metabolism at Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine — one of China's most prestigious general hospitals and the national leader in diabetes and metabolic disease research and clinical care. She is one of China's most distinguished endocrinologists and diabetes specialists, internationally recognized for her landmark contributions to the epidemiology, genetics, and clinical management of type 2 diabetes and metabolic syndrome in Chinese and Asian populations.
Academician Jia's election to the Chinese Academy of Engineering — China's highest honor in engineering and applied sciences — reflects the transformative impact of her research on diabetes prevention, diagnosis, and treatment in China. Her work has directly shaped national diabetes screening programs, clinical guidelines, and public health policy, and her research on the unique metabolic characteristics of Chinese patients with diabetes has contributed to a global reappraisal of diabetes risk thresholds and treatment targets in Asian populations.
Clinically, Academician Jia leads one of China's largest and most comprehensive diabetes and metabolic disease programs, managing patients with type 1 and type 2 diabetes, gestational diabetes, monogenic diabetes, metabolic syndrome, obesity, non-alcoholic fatty liver disease (NAFLD/MASH), and diabetic complications including nephropathy, retinopathy, neuropathy, and cardiovascular disease. Her program integrates endocrinology, cardiology, nephrology, ophthalmology, neurology, and nutrition to deliver multidisciplinary metabolic care at the highest level.
Hospital Affiliation: Shanghai Sixth People's Hospital
Shanghai Sixth People's Hospital (上海市第六人民医院) is affiliated with Shanghai Jiao Tong University School of Medicine and is one of Shanghai's most respected general hospitals. The Department of Endocrinology and Metabolism is a national key clinical specialty and one of the largest diabetes clinical and research programs in China, with a dedicated diabetes center, a metabolic disease research laboratory, and a multidisciplinary team that manages thousands of diabetes patients annually. The hospital is a national center for diabetes clinical trials and has been the site of landmark epidemiological studies that have defined the prevalence and characteristics of diabetes in China.
The department's research infrastructure includes a biobank of diabetes patient samples, a genomics program focused on the genetic architecture of type 2 diabetes in Chinese populations, and an active clinical trials program offering patients access to investigational glucose-lowering agents, novel insulin formulations, and metabolic surgery protocols.
Clinical Expertise
- Type 2 diabetes — individualized glycemic management; comprehensive cardiovascular risk reduction; GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, and novel glucose-lowering agents; insulin optimization; treatment of insulin resistance; management of diabetes in elderly patients
- Type 1 diabetes — intensive insulin therapy; continuous glucose monitoring (CGM) and insulin pump (CSII) therapy; closed-loop insulin delivery; management of hypoglycemia unawareness; transition from pediatric to adult care
- Gestational diabetes mellitus (GDM) — diagnosis and management; postpartum follow-up and long-term diabetes risk reduction
- Monogenic diabetes — MODY diagnosis and genetic testing; neonatal diabetes; treatment optimization based on genetic subtype
- Metabolic syndrome — integrated management of central obesity, dyslipidemia, hypertension, and insulin resistance; lifestyle intervention; pharmacological treatment
- Obesity and weight management — medical weight management; GLP-1/GIP receptor agonists (semaglutide, tirzepatide); metabolic surgery evaluation and coordination; post-bariatric follow-up
- Non-alcoholic fatty liver disease (NAFLD/MASH) — diagnosis and staging; lifestyle and pharmacological intervention; coordination with hepatology
- Diabetic complications — diabetic nephropathy (CKD management, SGLT-2 inhibitors, finerenone); diabetic retinopathy (coordination with ophthalmology); diabetic peripheral neuropathy; diabetic foot (multidisciplinary team); cardiovascular risk management in diabetes
- Diabetes and cardiovascular disease — integrated cardiometabolic risk management; GLP-1 agonists and SGLT-2 inhibitors for cardiovascular protection; coordination with cardiology
- Clinical trials — access to investigational glucose-lowering agents, novel insulin formulations, and metabolic intervention studies through Shanghai Sixth People's Hospital's active trials program
Academic Leadership & Research Contributions
Academician Jia Weiping is one of China's most prolific and internationally impactful diabetes researchers. She has authored and co-authored hundreds of peer-reviewed publications in journals including The Lancet, Nature Medicine, Diabetes Care, Diabetologia, and JAMA, with a research focus on the epidemiology of diabetes in China, the genetic architecture of type 2 diabetes in Asian populations, novel biomarkers for diabetes risk prediction, and the clinical outcomes of glucose-lowering therapies in Chinese patients.
Her landmark epidemiological studies — including large-scale national surveys of diabetes prevalence in China — have been cited globally and have directly informed WHO and IDF estimates of the global diabetes burden. Her research on the metabolic characteristics of Chinese patients with diabetes, including the role of visceral adiposity, postprandial hyperglycemia, and beta-cell dysfunction, has contributed to a global reappraisal of diabetes risk thresholds and treatment targets in Asian populations.
Academician Jia is a past president of the Chinese Diabetes Society (CDS) and has served on the scientific advisory boards of major international diabetes organizations including the International Diabetes Federation (IDF) and the Asian Association for the Study of Diabetes (AASD). She has been a keynote speaker at ADA, EASD, IDF, and AASD congresses, and is recognized globally as one of the most influential voices in diabetes medicine.
Why International Patients Choose Academician Jia Weiping
For international patients with complex or difficult-to-manage diabetes — including those with multiple complications, treatment-refractory hyperglycemia, rare forms of diabetes, or significant cardiovascular or renal comorbidities — Academician Jia's program at Shanghai Sixth People's Hospital offers a level of clinical expertise, multidisciplinary integration, and research-driven care that is genuinely world-class.
For patients of Asian descent, Academician Jia's deep expertise in the specific metabolic characteristics of Asian patients with diabetes — including the tendency toward beta-cell dysfunction at lower BMI thresholds, the importance of postprandial glucose control, and the cardiovascular risk profile of Asian diabetic patients — means that treatment strategies are tailored to the patient's actual metabolic phenotype rather than applied from guidelines developed primarily in Western populations.
For patients seeking access to the latest glucose-lowering agents — including GLP-1/GIP receptor agonists (tirzepatide), SGLT-2 inhibitors, and novel insulin formulations — Shanghai Sixth People's Hospital's clinical trials program and early access to approved agents in China provides options that may not yet be available or reimbursed in the patient's home country.
Treatment costs at Shanghai Sixth People's Hospital are substantially lower than equivalent endocrinology and diabetes care in Western healthcare systems, and the speed of access to specialist consultation and comprehensive metabolic workup is typically far faster than in public healthcare systems abroad. CMCS has coordinated diabetes consultations and treatment programs for patients from North America, Europe, Southeast Asia, and the Middle East through Academician Jia's department.
What to Expect at Your Consultation
Consultations with Academician Jia begin with a comprehensive review of all prior diabetes history, glycemic records (HbA1c trends, CGM data if available), current medications, complication screening results (renal function, urine albumin, retinal examination, nerve conduction studies, cardiac evaluation), and relevant comorbidity information. CMCS will arrange certified translation of all medical records in advance.
Academician Jia will assess the patient's metabolic phenotype, identify gaps in complication screening, outline the recommended treatment strategy with rationale, discuss clinical trial eligibility, and provide a clear monitoring and follow-up plan. For patients with multiple complications, a multidisciplinary assessment involving nephrology, ophthalmology, cardiology, and nutrition will be coordinated as appropriate. A written English-language consultation summary is provided after every appointment.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking diabetes and metabolic disease consultation with Academician Jia Weiping at Shanghai Sixth People's Hospital. Our services include priority consultation scheduling, certified medical record translation, pre-consultation laboratory and imaging review, treatment logistics and pharmacy coordination, on-site interpretation, and ongoing follow-up coordination between Academician Jia's team and the patient's home endocrinologist or primary care physician.
0 comentarios